Component
Colorectal-cancer-specific survival
Colorectal-cancer-specific survival. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Among 964 colorectal cancer patients, regular aspirin use after diagnosis was associated with superior colorectal-cancer-specific survival in those with mutated-PIK3CA cancers, multivariate hazard ratio for cancer-related death 0.18 with 95% confidence interval 0.06 to 0.61, and superior overall survival at hazard ratio 0.54, whereas among patients with wild-type PIK3CA there was no association with cancer-specific survival at hazard ratio 0.96 or overall survival at 0.94, with the interaction between aspirin and PIK3CA yielding a p value of 0.009.
Experimental context and source evidence
- availability_state
- biomarker_context Imported condition classification; unverified.
- evidence_span
- {"source_cache": "artifacts/aspirin-research/23094721.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0fab66fe6fa87b7288d31cfbda54b13b3a1d81fd32302054aa4c791b9d6ede43", "start_char": 0, "end_char": 2456, "text_sha256": "0fab66fe6fa87b7288d31cfbda54b13b3a1d81fd32302054aa4c791b9d6ede43"}
- experimental_model
- Molecular pathological epidemiology in 964 colorectal cancer patients from the Nurses’ Health Study and the Health Professionals Follow-up Study
- exposure
- Regular aspirin use after diagnosis, stratified by tumour PIK3CA mutation status
- limitations
- Observational cohorts with tumour genotyping, not a randomised trial, so aspirin use after diagnosis is chosen rather than assigned and may travel with other differences between patients.
- nutrient_topic
- Aspirin research collection; topical membership is not evidence of a direct clinical effect, and aspirin is recorded separately from salicylate, the metabolite it becomes. · Aspirin / acetylsalicylic acid
- organism
- Human
- plain_language
- Aspirin after diagnosis tracked with much better survival, but only in tumours carrying one particular mutation.
- primary_references
- [asa-p23094721] Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. (2012). https://pubmed.ncbi.nlm.nih.gov/23094721/ DOI: 10.1056/nejmoa1207756
- tissue_or_cell_type
- Colorectal tumour
- trigger_kind
- biomarker_context Imported condition classification; unverified.
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Molecular pathological epidemiology in 964 colorectal cancer patients from the Nurses’ Health Study and the Health Professionals Follow-up Study · source_derived_draft · unverified_draft
### asa-benefit-tracks-pik3ca Among 964 colorectal cancer patients, regular aspirin use after diagnosis was associated with superior colorectal-cancer-specific survival in those with mutated-PIK3CA cancers, multivariate hazard ratio for cancer-related death 0.18 with 95% confidence interval 0.06 to 0.61, and superior overall survival at hazard ratio 0.54, whereas among patients with wild-type PIK3CA there was no association with cancer-specific survival at hazard ratio 0.96 or overall survival at 0.94, with the interaction between aspirin and PIK3CA yielding a p value of 0.009. Condition category: biomarker_context nutrient_topic: Aspirin research collection; topical membership is not evidence of a direct clinical effect, and aspirin is recorded separately from salicylate, the metabolite it becomes. plain_language: Aspirin after diagnosis tracked with much better survival, but only in tumours carrying one particular mutation. organism: Human tissue_or_cell_type: Colorectal tumour experimental_model: Molecular pathological epidemiology in 964 colorectal cancer patients from the Nurses’ Health Study and the Health Professionals Follow-up Study limitations: Observational cohorts with tumour genotyping, not a randomised trial, so aspirin use after diagnosis is chosen rather than assigned and may travel with other differences between patients. exposure: Regular aspirin use after diagnosis, stratified by tumour PIK3CA mutation status evidence_span: {"source_cache": "artifacts/aspirin-research/23094721.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0fab66fe6fa87b7288d31cfbda54b13b3a1d81fd32302054aa4c791b9d6ede43", "start_char": 0, "end_char": 2456, "text_sha256": "0fab66fe6fa87b7288d31cfbda54b13b3a1d81fd32302054aa4c791b9d6ede43"} [asa-p23094721] Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. (2012). https://pubmed.ncbi.nlm.nih.gov/23094721/ DOI: 10.1056/nejmoa1207756
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.